EUVIMEDEUVIMED entdecken
Crossref

Anifrolumab for the treatment of cutaneous lupus erythematosus: a 10-case series

Maria Elena Hernández-Salas, Celia Horcajada-Reales, Carlos Palomar-Prieto, Laura Fernández-de la Fuente, Sara Herrero-Ruiz, Ana Martínez-Lauwers Dolz, Alberto Romero-Maté

Clinical and Experimental Dermatology · 25.09.2025 · 50 (10) · 2040-2043

DOI: 10.1093/ced/llaf272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 19.06.2025. Verfasst von Maria Elena Hernández-Salas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Fuenlabrada University Hospital, Fuenlabrada, Madrid, Spain. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Lupus Erythematosus, Cutaneous. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anifrolumab is a monoclonal antibody that targets the type I interferon receptor subunit 1. It was approved for the treatment of systemic lupus erythematosus by the US Food and Drug Administration in 2021 and by the European Medicines Agency in 2022. Although phase III clinical trials reported a statistically significant improvement in skin lesions, anifrolumab has not yet been approved for the treatment of cutaneous lupus erythematosus. We present a case series that includes 10 patients with cutaneous lupus erythematosus who demonstrated a rapid and sustained response to anifrolumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedLupus Erythematosus, CutaneousAdultAgedFemaleHumansMaleMiddle AgedTreatment Outcome

Substanzen

anifrolumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Dermatology Department, Fuenlabrada University Hospital, Fuenlabrada, Madrid, Spain.

Zitieren

APA

Hernández-Salas, M. E., Horcajada-Reales, C., Palomar-Prieto, C., Fernández-de la Fuente, L., Herrero-Ruiz, S., Martínez-Lauwers Dolz, A., & Romero-Maté, A. (2025). Anifrolumab for the treatment of cutaneous lupus erythematosus: a 10-case series. Clinical and Experimental Dermatology, 50(10), 2040-2043. https://doi.org/10.1093/ced/llaf272

Vancouver

Hernández-Salas ME, Horcajada-Reales C, Palomar-Prieto C, Fernández-de la Fuente L, Herrero-Ruiz S, Martínez-Lauwers Dolz A, et al. Anifrolumab for the treatment of cutaneous lupus erythematosus: a 10-case series. Clinical and Experimental Dermatology. 2025;50(10):2040-2043. doi:10.1093/ced/llaf272

BibTeX
@article{HernndezSalas2025,
  author = {Hernández-Salas, Maria Elena and Horcajada-Reales, Celia and Palomar-Prieto, Carlos and Fernández-de la Fuente, Laura and Herrero-Ruiz, Sara and Martínez-Lauwers Dolz, Ana and Romero-Maté, Alberto},
  title = {Anifrolumab for the treatment of cutaneous lupus erythematosus: a 10-case series},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  volume = {50},
  number = {10},
  pages = {2040--2043},
  doi = {10.1093/ced/llaf272}
}
Kostenlos starten →